Product Description
A transforming growth factor (TGF)-beta2 specific phosphorothioate antisense oligodeoxynucleotide with the sequence 5'-CGGCATGTCTATTTTGTA-3', with potential antineoplastic activity. Trebedersen binds to TGF-beta2 mRNA causing inhibition of protein translation, thereby decreasing TGF-beta2 protein levels; decreasing intratumoral TGF-beta2 levels may result in the inhibition of tumor cell growth and migration, and tumor angiogenesis. TGF-beta2, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trabedersen)
Mechanisms of Action: TGFb Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous, Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Isarna
Company Location: Europe
Company Founding Year: 2014
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Oncotelic presented P1 Oncology Solid Tumor Unspecified results on 2025-03-25 for Trabedersen
- Clinical Outcomes Reported - Oncotelic presented P3 Pancreatic Cancer|Glioblastoma results on 2024-06-17 for Trabedersen
Highest Development Phases
Phase 3: Adenocarcinoma|Myopia, Degenerative|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Phase 2: Mesothelioma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05425576 |
OT-01-M201 | P2 |
Not yet recruiting |
Mesothelioma |
2028-12-01 |
44% |
2024-03-16 |
Primary Completion Date|Primary Endpoints |
NCT04770610 |
OT_101_001 | P3 |
Active, not recruiting |
Myopia, Degenerative |
2027-03-01 |
14% |
2023-08-09 |
Primary Endpoints|Treatments|Trial Status |
NCT06079346 |
STOP-PC | P3 |
Recruiting |
Pancreatic Cancer|Pancreatic Ductal Carcinoma|Adenocarcinoma |
2026-06-01 |
7% |
2024-05-22 |
Primary Endpoints|Treatments|Trial Status |